{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T19:13:30Z","timestamp":1757704410817},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"17-18","license":[{"start":{"date-parts":[[2012,7,18]],"date-time":"2012-07-18T00:00:00Z","timestamp":1342569600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Wien Med Wochenschr"],"published-print":{"date-parts":[[2013,9]]},"DOI":"10.1007\/s10354-012-0125-9","type":"journal-article","created":{"date-parts":[[2012,7,17]],"date-time":"2012-07-17T09:47:00Z","timestamp":1342518420000},"page":"391-396","source":"Crossref","is-referenced-by-count":8,"title":["Bone turnover in hyperparathyroidism"],"prefix":"10.1007","volume":"163","author":[{"given":"Katharina","family":"Kerschan-Schindl","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,7,18]]},"reference":[{"issue":"Suppl","key":"125_CR1","first-page":"12","volume":"17","author":"LJ Melton","year":"2002","unstructured":"Melton LJ III. The epidemiology of primary hyperparathyroidism in North America. J Bone Miner Res. 2002;17(Suppl 2):12\u201317.","journal-title":"J Bone Miner Res."},{"key":"125_CR2","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1359\/JBMR.050910","volume":"21","author":"RA Wermers","year":"2006","unstructured":"Wermers RA, Koshla S, Atkinson EJ, et al. Incidence of primary hyperparathyroidism in Rochester, Minnesota, 1993\u20132011: an update on the changing epidemiology of the disease. J Bone Miner Res. 2006;21:171\u20137.","journal-title":"J Bone Miner Res."},{"key":"125_CR3","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/8756-3282(86)90020-7","volume":"7","author":"EF Eriksen","year":"1986","unstructured":"Eriksen EF, Mosekilde L, Melsen F. Bone remodeling and balance in primary hyperparathyroidism. Bone. 1986;7:213\u201321.","journal-title":"Bone."},{"key":"125_CR4","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/BF02115782","volume":"69","author":"P Pietschmann","year":"1991","unstructured":"Pietschmann P, Niederle B, Anvari A, et al. Serum osteocalcin levels in primary hyperparathyroidism. Klin Wochenschr. 1991;69:351\u20133.","journal-title":"Klin Wochenschr."},{"key":"125_CR5","doi-asserted-by":"crossref","first-page":"4655","DOI":"10.1210\/jc.2003-030470","volume":"88","author":"Q Chen","year":"2003","unstructured":"Chen Q, Kaji H, Iu MF, et al. Effects of an excess and a deficiency of endogenous parathyroid hormone on volumetric bone mineral density and bone geometry determined by peripheral quantitative computed tomography in female subjects. J Clin Endocrinol Metab. 2003;88:4655\u20138.","journal-title":"J Clin Endocrinol Metab."},{"key":"125_CR6","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1359\/jbmr.1999.14.10.1700","volume":"14","author":"S Khosla","year":"1999","unstructured":"Khosla S, Melton LJ III, Wermers RA, et al. Primary hyperparathyroidism and the risk of fracture: a population-based study. J Bone Miner Res. 1999;14:1700\u20137.","journal-title":"J Bone Miner Res"},{"key":"125_CR7","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1136\/bmj.321.7261.598","volume":"321","author":"P Vestergaard","year":"2000","unstructured":"Vestergaard P, Mollerup CL, Frokjaer V, et al. Chort study of risk of fracture before and after surgery for primary hyperparathyroidism. Br Med J. 2000;321:598\u2013602.","journal-title":"Br Med J."},{"key":"125_CR8","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1210\/jc.74.3.481","volume":"74","author":"MJ Seibl","year":"1992","unstructured":"Seibl MJ, Gartenberg F, Silverberg SJ, et al. Urinary hydroxypyridinium cross-links of collagen in primary hyperparathyroidism. J Clin Endocrinol Metab. 1992;74:481\u20136.","journal-title":"J Clin Endocrinol Metab."},{"key":"125_CR9","doi-asserted-by":"crossref","first-page":"3487","DOI":"10.1210\/jc.81.10.3487","volume":"81","author":"CY Guo","year":"1996","unstructured":"Guo CY, Thomas WEG, Al-Dehaimi AW, et al. Longitudinal changes in bone mineral density and bone turnover in postmenopausal women with primary hyperparathyroidism. J Clin Endocrinol Metab. 1996;81:3487\u201391.","journal-title":"J Clin Endocrinol Metab."},{"key":"125_CR10","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S8756-3282(97)00078-1","volume":"21","author":"P Christiansen","year":"1997","unstructured":"Christiansen P, Steiniche T, Brixen K, et al. Primary hyperparathyroidism: biochemical markers and bone mineral density at multiple skeletal sites in Danish patients. Bone. 1997;21:93\u20139.","journal-title":"Bone."},{"issue":"Suppl","key":"125_CR11","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/S0753-3322(00)80021-9","volume":"54","author":"S Suzuki","year":"2000","unstructured":"Suzuki S, Fukushima T, Ami H, et al. Pre- and postoperative bone metabolism of primary hyperparathyroidism. Biomed Pharmacoth. 2000;54(Suppl 1):90\u201396.","journal-title":"Biomed Pharmacoth."},{"key":"125_CR12","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1046\/j.1365-2265.2000.00900.x","volume":"52","author":"Y Abe","year":"2000","unstructured":"Abe Y, Ejima E, Fujiyama K, et al. Parathyroidectomy for primary hyperparathyroidism induces positive uncoupling and increases bone mineral density in cancellous bones. Clin Endocrinol. 2000;52:203\u20139.","journal-title":"Clin Endocrinol."},{"key":"125_CR13","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1530\/eje.0.1420451","volume":"142","author":"CY Guo","year":"2000","unstructured":"Guo CY, Holand PA, Jackson BF, et al. Immediate changes in biochemical markers of bone turnover and circulating interleukin-6 after parathyroidectomy for primary hyperparathyroidism. Eur J Endocrinol. 2000;142:451\u20139.","journal-title":"Eur J Endocrinol."},{"key":"125_CR14","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1507\/endocrj.47.231","volume":"47","author":"D Nakaoka","year":"2000","unstructured":"Nakaoka D, Sugimoto T, Kobayashi T, et al. Evaluation of changes in bone density and biochemical parameters after parathyroidectomy in primary hyperparathyroidism. Endocrine Journal. 2000;47:231\u20137.","journal-title":"Endocrine Journal."},{"key":"125_CR15","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/8756-3282(92)90360-9","volume":"13","author":"P Christiansen","year":"1992","unstructured":"Christiansen P, Steiniche T, Vesterby A, et al. Primary hyperparathyroidism: iliac crest trabecular boen volume, structure, remodeling, and balance evaluated by histomorphometric methods. Bone. 1992;13:41\u20139.","journal-title":"Bone"},{"key":"125_CR16","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/S0039-6060(97)90328-7","volume":"122","author":"K Thorsen","year":"1997","unstructured":"Thorsen K, Kristoffersson AO, Lorentzon RP. Changes in bone mass and serum markers of bone metabolism after parathyroidectomy. Surgery. 1997;122:882\u20137.","journal-title":"Surgery."},{"key":"125_CR17","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/S8756-3282(99)00150-7","volume":"25","author":"P Christiansen","year":"1999","unstructured":"Christiansen P, Steiniche T, Brixen K, et al. Primary hyperparathyroidism: short term changes in bone remodeling and bone mineral density following parathyroidectomy. Bone. 1999;25:237\u201344.","journal-title":"Bone."},{"key":"125_CR18","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s002230050004","volume":"66","author":"B Cortet","year":"2000","unstructured":"Cortet B, Cortet C, Blanckaert F, et al. Bone ultrasonometry and turnover markers in primary hyperparathyroidism. Calcif Tissue Int. 2000;66:11\u20135.","journal-title":"Calcif Tissue Int."},{"key":"125_CR19","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/S8756-3282(00)00260-X","volume":"26","author":"T Steiniche","year":"2000","unstructured":"Steiniche T, Christiansen P, Vesterby A, et al. Primary hyperparathyroidism: bone structure, balance, and remodeling before and 3 years after surgical treatment. Bone. 2000;26:535\u201343.","journal-title":"Bone."},{"key":"125_CR20","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/BF03343897","volume":"24","author":"V Carnevale","year":"2001","unstructured":"Carnevale V, Pacitti MT, Pileri M, et al. Short-term effects of surgery in post-menopausal patients with primary hyperparathyroidism and normal bone turnover. Endocrinol Invest. 2001;24:575\u20139.","journal-title":"Endocrinol Invest."},{"key":"125_CR21","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/s00223-001-1142-7","volume":"73","author":"F Lumachi","year":"2003","unstructured":"Lumachi F, Ermani M, Basso SMM, et al. Short- and long-term changes in bone mineral density of the lumbar spine after parathyroidectomy in patients with primary hyperparathyroidism. Calcif Tissue Int. 2003;73:44\u20138.","journal-title":"Calcif Tissue Int."},{"key":"125_CR22","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000098223","volume":"143","author":"M Rauner","year":"2007","unstructured":"Rauner M, Sipos W, Pietschmann P. Osteoimmunology. Int Arch Allergy Immunol. 2007;143:31\u201348.","journal-title":"Int Arch Allergy Immunol"},{"key":"125_CR23","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1186\/1471-2350-12-168","volume":"12","author":"M Piedra","year":"2011","unstructured":"Piedra M, Garcia-Unzueta MT, Berja A, et al. Single nucleotide polymorphisms of the OPG\/RANKL system genes in primary hyperparathyroidism and their relationship with boen mineral density. BMC Med Genet. 2011;12:168\u201376.","journal-title":"BMC Med Genet."},{"key":"125_CR24","unstructured":"Fraher U, Watson PH, Kisiel M, et al. Measurement of circulating osteoprotegerin (OPG) in human sera: inhibition of circulating OPG in osteoporotic patients treated with hPTH (1\u201334). 2000; ASBMR, Toronto (abstract)."},{"key":"125_CR25","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1210\/jc.2007-1645","volume":"93","author":"IA Nakchbandi","year":"2008","unstructured":"Nakchbandi IA, Lang R, Kinder B, et al. The role of the receptor activator of nuclear factor-kB ligand\/osteoprotegerin cytokine system in primary hyperparathyroidism. J Clin Endocrinol Metab. 2008;93:967\u201373.","journal-title":"J Clin Endocrinol Metab."},{"key":"125_CR26","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1007\/s00223-002-2100-8","volume":"73","author":"LS Stilgren","year":"2003","unstructured":"Stilgren LS, Heged\u00fcs LM, Beck-Nielsen H, et al. Osteoprotegerin levels in primary hyperparathyroidism: effect of parathyroidectomy and association with bone metabolism. Calcif Tissue Int. 2003;73:210\u2013216.","journal-title":"Calcif Tissue Int."},{"key":"125_CR27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1055\/s-0031-1297971","volume":"44","author":"K Kerschan-Schindl","year":"2012","unstructured":"Kerschan-Schindl K, Riss P, Krestan C, et al. Bone metabolism in patients with primary hyperparathyroidism before and after surgery. Horm Metab Res. 2012;44:1\u20136.","journal-title":"Horm Metab Res."},{"key":"125_CR28","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.bone.2004.03.012","volume":"35","author":"LS Stilgren","year":"2004","unstructured":"Stilgren LS, Rettmer E, Heged\u00fcs LM, et al. Skeletal changes in osteoprotegerin and receptor activator of nuclear factor-kB ligand mRNA levels in primary hyperparathyroidism: effect of parathyroidectomy and association with bone metabolism. Bone. 2004;35:256\u201365.","journal-title":"Bone."},{"key":"125_CR29","doi-asserted-by":"crossref","first-page":"4577","DOI":"10.1210\/en.2005-0239","volume":"146","author":"T Bellido","year":"2005","unstructured":"Bellido T, Ali AA, Gubrij I, et al. Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: a novel mechanism for hormonal control of osteoblastogenesis. Endocrinology. 2005;146:4577\u201383.","journal-title":"Endocrinology."},{"key":"125_CR30","doi-asserted-by":"crossref","first-page":"e2942","DOI":"10.1371\/journal.pone.0002942","volume":"3","author":"CA O\u2019Brien","year":"2008","unstructured":"O\u2019Brien CA, Plotkin LI, Galli C, et al. Control of bone mass and remodeling by PTH receptor signaling in osteocytes. PLoS ONE. 2008;3:e2942 (Zit 8 von Van Lierop AH et al Eur J Endocrinol 2010;163:833\u2013837).","journal-title":"PLoS ONE."},{"key":"125_CR31","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1055\/s-0031-1275661","volume":"119","author":"H Kaji","year":"2011","unstructured":"Kaji H, Imanishi Y, Sugimoto T, Seino S. Comparisons of serum sclerostin levels among patients with postmenopausal osteoporosis, primary hyperparathyroidism and osteomalacia. Exp Clin Endocrinol Diabetes. 2011;119:440\u20134.","journal-title":"Exp Clin Endocrinol Diabetes."},{"key":"125_CR32","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1530\/EJE-10-0699","volume":"163","author":"AH Van Lierop","year":"2010","unstructured":"Van Lierop AH, Witteveen JE, Handy NAT, et al. Patients with primary hyperparathyroidism have lower circulating sclerostin levels than euparathyroid controls. Eur J Endocrinol. 2010;163:833\u20137.","journal-title":"Eur J Endocrinol."},{"issue":"6","key":"125_CR33","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1007\/s00198-011-1806-8","volume":"23","author":"MSM Ardawi","year":"2011","unstructured":"Ardawi MSM, Al-Sibiany AM, Bakhsh TM, et al. Decreased serum sclerostin levels in patients with primary hyperparathyroidism: a cross-sectional and a longitudinal study. Osteoporos Int. 2011;23(6):1789\u201397.","journal-title":"Osteoporos Int"},{"key":"125_CR34","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.maturitas.2009.09.011","volume":"64","author":"M Munoz-Torres","year":"2009","unstructured":"Munoz-Torres M, Reyes-Garcia R, Mezquita-Raya P, et al. Serum cathepsin K as a marker of bone metabolism in postmenopausal women treated with a Alendronate. Maturitas. 2009;64:188\u201392.","journal-title":"Maturitas"},{"key":"125_CR35","doi-asserted-by":"crossref","first-page":"4489","DOI":"10.1210\/jc.2004-0724","volume":"89","author":"A Gupta","year":"2004","unstructured":"Gupta A, Winer K, Econs MJ, et al. FGF-23 is elevated by chronic hyperphosphatemia. J Clin Endocrinol Metab. 2004;89:4489\u201392.","journal-title":"J Clin Endocrinol Metab."},{"key":"125_CR36","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1530\/eje.0.1510055","volume":"151","author":"H Yamashita","year":"2004","unstructured":"Yamashita H, Yamashita T, Miyamoto M, et al. Fibroblast growth factor (FGF)-23 in patients with primary hyperparathyroidism. Eur J Endocrinol. 2004;151:55\u201360.","journal-title":"Eur J Endocrinol."},{"key":"125_CR37","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1530\/eje.1.02053","volume":"154","author":"K Kobayashi","year":"2006","unstructured":"Kobayashi K, Imanishi Y, Miyauchi A, et al. Regulation of plasma fibroblast growth factor 23 by calcium in primary hyperparathyroidism. Eur J Endocrinol. 2006;154:93\u20139.","journal-title":"Eur J Endocrinol."},{"key":"125_CR38","doi-asserted-by":"crossref","first-page":"2683","DOI":"10.1681\/ASN.2006070783","volume":"18","author":"T Kawata","year":"2007","unstructured":"Kawata T, Imanishi Y, Kobayashi K, et al. Parathyroid hormone regulated fibroblast growth factor-23 in a mouse model of primary hyperparathyroidism. J Am Soc Nephrol. 2007;18:2683\u20138.","journal-title":"J Am Soc Nephrol."},{"key":"125_CR39","doi-asserted-by":"crossref","first-page":"4152","DOI":"10.1210\/jc.2008-0564","volume":"93","author":"P Bj\u00f6rklund","year":"2008","unstructured":"Bj\u00f6rklund P, Krajisnik T, Akerstr\u00f6m G, et al. Type I Membrane Klotho expression is decreased and inversely correlated to serum calcium in primary hyperparathyroidism. J Clin Endocrinol Metab. 2008;93:4152\u20137.","journal-title":"J Clin Endocrinol Metab."},{"key":"125_CR40","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.cmet.2009.12.007","volume":"11","author":"J Guo","year":"2010","unstructured":"Guo J, Liu M, Yand D, et al. Suppression of Wnt signaling by Dkk1 attenuated PTH-mediated stromal cell response and new bone formation. Cell Metabolism. 2010;11:161\u201371.","journal-title":"Cell Metabolism."},{"key":"125_CR41","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1210\/jc.2008-1763","volume":"94","author":"JP Bilezikian","year":"2009","unstructured":"Bilezikian JP, Khan AA, Potts JT. On behalf of the third international workshop on the management of asymptomatic primary hyperparathyroidism. Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the third international Workshop. J Clin Endocrinol Metab. 2009;94:335\u20139.","journal-title":"J Clin Endocrinol Metab."},{"key":"125_CR42","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1530\/eje.0.1460783","volume":"146","author":"E Vignali","year":"2002","unstructured":"Vignali E, Picone A, Materazzi G, et al. A quick intraoperative parathyroid hormone assay in the surgical management of patients with primary hyperparathyroidism: a study of 206 consecutive cases. Eur J Endocrinol. 2002;146:783\u20138.","journal-title":"Eur J Endocrinol"},{"key":"125_CR43","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/S8756-3282(99)00207-0","volume":"25","author":"P Christiansen","year":"1999","unstructured":"Christiansen P, Steiniche T, Brixen K, et al. Primary hyperparathyroidism: effect of parathyroidectomy on regional boen mienral density in Danish patients: a three-year follow-up study. Bone. 1999;25:589\u201395.","journal-title":"Bone."},{"key":"125_CR44","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1210\/jc.80.3.729","volume":"80","author":"SJ Silverberg","year":"1995","unstructured":"Silverberg SJ, Gartenberg F, Jacobs TP, et al. Increased bone mineral density after parathyroidectomy in primary hyperparathyroidism. J Clin Endocrinol Metab. 1995;80:729\u201334.","journal-title":"J Clin Endocrinol Metab."},{"key":"125_CR45","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1056\/NEJMcp1106636","volume":"365","author":"C Marocci","year":"2011","unstructured":"Marocci C, Cetami F. Primary hyperparathyroidism. N Engl J Med. 2011;365:2389\u201397.","journal-title":"N Engl J Med."},{"key":"125_CR46","doi-asserted-by":"crossref","first-page":"3319","DOI":"10.1210\/jc.2003-030908","volume":"89","author":"AA Kahn","year":"2004","unstructured":"Kahn AA, Bilezikian JP, Kung AWC, et al. Alendronate in primary hyperparathyroidism: a double-blind, randomized, placebo-controlled trial. J Clin Endocrinol Metab. 2004;89:3319\u201325.","journal-title":"J Clin Endocrinol Metab."},{"key":"125_CR47","doi-asserted-by":"crossref","first-page":"360","DOI":"10.7326\/0003-4819-125-5-199609010-00002","volume":"125","author":"AB Grey","year":"1996","unstructured":"Grey AB, Stapleton JP, Evans MC, et al. Effect of hormone replacement therapy on bone mineral density in postmenopausal women with mild primary hyperparathyroidism: a randomized, controlled trial. Ann Int Med. 1996;125:360\u20138.","journal-title":"Ann Int Med."},{"key":"125_CR48","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1210\/er.22.4.477","volume":"22","author":"P Lips","year":"2001","unstructured":"Lips P. Vitamin D deficiency and secondary hyperparathyroidism in the elderly: consequences for bone loss and fractures and therapeutic implications. Endocr Rev. 2001;22:477\u2013501.","journal-title":"Endocr Rev."},{"key":"125_CR49","doi-asserted-by":"crossref","first-page":"913","DOI":"10.2215\/CJN.06040710","volume":"6","author":"J Cunningham","year":"2011","unstructured":"Cunningham J, Locatelli F, Rodriguez M. Secondary hyperparathyroidism: pathogenesis, disease progression, and therapeutic options. Clin J Am Soc Nephrol. 2011;6:913\u201321.","journal-title":"Clin J Am Soc Nephrol."},{"key":"125_CR50","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/S0272-6386(03)00404-9","volume":"42","author":"G Ekoyan","year":"2003","unstructured":"Ekoyan G, Levin A, Levin NW. K\/DOIQI clinical practice guidelines on bone metabolism and disease in chronic kidney disease. Am J Kidney Dis. 2003;42:12\u201328, 52\u201357.","journal-title":"Am J Kidney Dis."},{"issue":"Suppl","key":"125_CR51","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/j.1744-9987.2011.00924.x","volume":"15","author":"M Okada","year":"2011","unstructured":"Okada M, Tominaga Y, Izumi K, et al. Tertiary hyperparathyroidism resistant o cinacalcet treatment. Ther Apher Dial. 2011;15(Suppl 1):33\u20137.","journal-title":"Ther Apher Dial."}],"container-title":["Wiener Medizinische Wochenschrift"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10354-012-0125-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10354-012-0125-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10354-012-0125-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,29]],"date-time":"2019-05-29T12:11:04Z","timestamp":1559131864000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10354-012-0125-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,7,18]]},"references-count":51,"journal-issue":{"issue":"17-18","published-print":{"date-parts":[[2013,9]]}},"alternative-id":["125"],"URL":"https:\/\/doi.org\/10.1007\/s10354-012-0125-9","relation":{},"ISSN":["0043-5341","1563-258X"],"issn-type":[{"value":"0043-5341","type":"print"},{"value":"1563-258X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,7,18]]}}}